Compare New York Times Co (NYT) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
New York Times Co vs Pfizer Inc — how do they compare? New York Times Co trades at $66.6 (market cap $10.74B), while Pfizer Inc trades at $27.71 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 14.8× New York Times Co's market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold New York Times Co for 81 Days and Pfizer Inc for 158 Days on average.
| NYT | PFE | |
|---|---|---|
Market Cap | $10.74B | $158.56B |
Volume | 2,096,352 | 44,138,282 |
Sector | Media | Health |
52-Week High | $85.86 | $29.02 |
52-Week Low | $54.66 | $23.67 |
Typical Hold Time | 81 Days | 158 Days |
Enterprise Value | $10.14B | $210.06B |
Dividend Yield | 1.38% | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The New York Times Company (NYT) trades at $64.90, up 1.3% with strong fundamentals including 12.17% net margin and consistent earnings beats. Technical indicators show bearish momentum with support at $62-64 and resistance at $65-67. Recent news highlights dividend declaration and ongoing AI copyright litigation.
Outlook remains positive with 35% analyst buy ratings and $84 consensus target, though legal risks and technical bearish signals warrant caution. Revenue growth trajectory and strong profitability support long-term value despite near-term headwinds.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
